Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GH Research (GHRS)
NASDAQ:GHRS
Holding GHRS?
Track your performance easily
GHRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.05 - $14.99
Previous Close$9.27
Volume28.83K
Average Volume (3M)57.62K
Market Cap
$481.26M
Enterprise Value$377.33M
Total Cash (Recent Filing)$105.94M
Total Debt (Recent Filing)$974.00K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Feb 27, 2025EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding52,028,145
10 Day Avg. Volume87,540
30 Day Avg. Volume57,619
Standard Deviation0.19
R-Squared0.04
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.60
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.49K
Forecast
1Y Price Target
$31.25Price Target Upside237.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
GH Research News
PremiumCompany Announcements
GH Research Q3 2024 Results and Clinical Updates
PremiumCompany Announcements
GH Research Faces Growing Losses in Q3 2024
PremiumCompany Announcements
GH Research Advances Psychedelic TRD Treatment Trials
PremiumCompany Announcements
GH Research Engages Investors at Healthcare Conference
PremiumCompany Announcements
GH Research to Engage at Global Investment Conference
PremiumCompany Announcements
GH Research to Connect at Global Healthcare ConferenceBulls Say, Bears Say
Bulls Say
Analyst RecommendationsAnalyst reiterates a Buy rating on GHRS shares.
Clinical TrialsEnrollment in the European Phase 2b trial evaluating GH001 in patients with treatment-resistant depression is on track with top-line data expected.
Financial PerformanceGHRS' cash balance at the end of Q3 was $193.8MM, which should provide a cash runway into 2026.
Bears Say
Clinical TrialsRecruitment for the proof-of-concept trial for GH001 for bipolar depression in Type 2 bipolar disorder remains slow, leading to an end of the trial soon.
Leadership ChangeThe unexpected transition of the CEO led to weakness in the stock, which closed down approximately 7%.
Regulatory ChallengesThe company is working towards getting the FDA's clinical hold removed on its investigational new drug application for GH001 in a proprietary inhalation device, indicating regulatory challenges.
---
Ownership Overview
―
Insiders
3.11% Mutual Funds
49.85% Other Institutional Investors
46.73% Public Companies and
Individual Investors
GHRS FAQ
What was GH Research’s price range in the past 12 months?
GH Research lowest stock price was $5.05 and its highest was $14.99 in the past 12 months.
What is GH Research’s market cap?
Currently, no data Available
When is GH Research’s upcoming earnings report date?
GH Research’s upcoming earnings report date is Feb 27, 2025 which is in 93 days.
How were GH Research’s earnings last quarter?
GH Research released its earnings results on Nov 14, 2024. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.016.
Is GH Research overvalued?
According to Wall Street analysts GH Research’s price is currently Undervalued.
Does GH Research pay dividends?
GH Research does not currently pay dividends.
What is GH Research’s EPS estimate?
GH Research’s EPS estimate is -$0.22.
How many shares outstanding does GH Research have?
GH Research has 52,028,145 shares outstanding.
What happened to GH Research’s price movement after its last earnings report?
GH Research reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went down -2.922%.
Which hedge fund is a major shareholder of GH Research?
Among the largest hedge funds holding GH Research’s share is RA Capital Management. It holds GH Research’s shares valued at 45M.
---
GH Research Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.25 (237.84% Upside)
$31.25 (237.84% Upside)
Blogger Sentiment
Bullish
GHRS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 122.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 23.7%
Last 30 Days ▲ 23.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
34.15%
12-Months-Change
Fundamentals
Return on Equity
-19.96%
Trailing 12-Months
Asset Growth
-14.17%
Trailing 12-Months
Company Description
GH Research
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
---
GHRS Stock 12 Month Forecast
Average Price Target
$31.25
▲(237.84% Upside)
Technical Analysis
Best Analysts Covering GHRS
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
-0.34%
reiterated a buy rating 8 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of -0.34% per trade.
---